The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b/2 study of pexidartinib (PEX) in combination with radiation therapy (XRT) and temozolomide (TMZ) in newly diagnosed glioblastoma.
 
Howard Colman
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Abbvie; Genentech; Insys Therapeutics; Novocure; Omniox; Roche
Research Funding - Abbvie; BeiGene; DNAtrix; Kadmon; Merck; Newlink Genetics; Orbus Therapeutics; Plexxikon
 
Jeffrey J. Raizer
Employment - Agenus; Celldex
Stock and Other Ownership Interests - Agenus; Cancer Action Now; Celldex; Exicure
Honoraria - ZIOPHARM Oncology
Consulting or Advisory Role - ZIOPHARM Oncology
Research Funding - AstraZeneca/MedImmune; Genentech/Roche; Merck; Novartis; Plexxikon; Stemline Therapeutics
 
Tobias Walbert
Consulting or Advisory Role - Abbvie; Tocagen
 
Scott Randall Plotkin
No Relationships to Disclose
 
Marc C. Chamberlain
No Relationships to Disclose
 
Eric T. Wong
Honoraria - Advanced Medical; Novocure; UpToDate
Research Funding - Five Prime Therapeutics; Novocure; Orbus Therapeutics; Plexxikon; Vascular Biogenics
 
Vinay K. Puduvalli
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - DePuy Companies; Foundation Medicine; Nektar; Orbus Therapeutics
Consulting or Advisory Role - Nektar; Novocure; Threshold Pharmaceuticals
Research Funding - DNAtrix; Genentech; Plexxikon
 
David A. Reardon
Honoraria - Abbvie; Bristol-Myers Squibb; Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Consulting or Advisory Role - Bristol-Myers Squibb; Cavion; Celldex; Genentech/Roche; Inovio Pharmaceuticals; Juno Therapeutics; Merck; Midatech Pharma; Momenta Pharmaceuticals; Monteris Medical; Novartis; Novocure; Oncorus; Oxigene; Regeneron; Stemline Therapeutics
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Midatech Pharma (Inst); Tragara (Inst)
 
Fabio Massaiti Iwamoto
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Merck; Novocure; Regeneron
Speakers' Bureau - Prime Oncology
 
Maciej M. Mrugala
No Relationships to Disclose
 
Brett Johnson
Travel, Accommodations, Expenses - Orbus Therapeutics
 
Karthik Sonty
No Relationships to Disclose
 
David Alan Karlin
Employment - Plexxikon
Consulting or Advisory Role - Apollo; Genentech; Orpheus Therapeutics; Plexxikon; Selecta Biosciences; Vivus
Patents, Royalties, Other Intellectual Property - Selecta Biosciences
 
Michael Pelayo
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
 
Marguerite Hutchinson
Employment - Plexxikon
Stock and Other Ownership Interests - Plexxikon
 
Henry Hsu
Consulting or Advisory Role - Plexxikon
Patents, Royalties, Other Intellectual Property - Allysta Pharmaceuticals